Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and
dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.